New Study Suggests Clinical Benefits Of Risperdal R ConstaTM In Patients With Recent Onset Psychosis

Patients with psychosis treated early on in the course of their illness with Risperdal ConstaTM (risperidone long-acting injection), demonstrated high response and remission rates with low relapse rates according to a preliminary study published in the April edition of the Journal of Clinical Psychopharmacology.

Antipsychotic Drugs Increase Risk Of Developing Pneumonia In Elderly - Nursing Home Patients At Particular Risk

Elderly patients who use antipsychotic drugs have a 60 percent increased risk of developing pneumonia compared to non-users. This risk is highest in the first week following prescription and decreases gradually thereafter. These findings are published in Journal of the American Geriatrics Society.

Mental Health Research Charity Honours Dr. Mei For Schizophrenia Studies

Studies of how brain cell communication may be altered in schizophrenia have earned Dr. Lin Mei, chief of developmental neurobiology at the Medical College of Georgia, a 2008 Distinguished Investigator Award from NARSAD.Dr.

Brain Chemical Imbalance May Explain Lack Of Motivation In Schizophrenia

A study of patients with psychotic illnesses such as schizophrenia suggests an alternative explanation for why many sufferers lack motivation. The research is described in BioMed Central's journal BMC Psychiatry.In addition to the hallucinations that often characterize schizophrenia, patients also have major problems with apathy and lack of motivation.

New Link To Schizophrenia Discovered By Hopkins Researchers

Neuroscientists at Johns Hopkins have discovered that mice lacking an enzyme that contributes to Alzheimer disease exhibit a number of schizophrenia-like behaviors. The finding raises the possibility that this enzyme may participate in the development of schizophrenia and related psychiatric disorders and therefore may provide a new target for developing therapies.

Schizophrenia - Risperidone Long-Acting Injection Extends Time To Relapse Compared To Oral Quetiapine

A new study, presented for the first time at an international psychiatric meeting, examined the time to relapse in patients with schizophrenia treated with risperidone long-acting injection (RLAI) or oral quetiapine. The data show that the mean time free from relapse for patients treated with RLAI was statistically longer than those treated with quetiapine (607 days RLAI versus 533 days with quetiapine, p.

Patients Treated With Risperidone Long Acting Injection Had A Significantly Longer Time To Relapse Compared To Quetiapine In Clinical Study

Nearly half of patients with schizophrenia fail to remain on their medication treatment, which can result in a relapse of symptoms (1, 2). Today, data from a new international study showed that patients treated with risperidone long-acting injection (RLAI) had a significantly longer time to relapse (3) compared to patients treated with an oral atypical medication, quetiapine.

Pharmacogenetic Findings May Lead To Individualized Treatment For Schizophrenia

Data presented at the APA Annual Meeting on Vanda Pharmaceuticals Inc.'s (NASDAQ: VNDA) investigational drug candidate, iloperidone, included its 4-week, short-term Phase III trial, as well as a pooled analysis of three long-term, 52-week trials, studying the efficacy and safety of iloperidone.

Abnormalities Found In Specific Brain Area Of Recently Diagnosed Schizophrenia Patients

Patients recently diagnosed with schizophrenia have abnormalities in a specific part of the brain's white matter. The study, published this month in the journal Neuropsychopharmacology, suggests that brain signals passing through the temporal lobe may get "crossed" and lead to some of the symptoms associated with schizophrenia.

Teva Receives Court Ruling Awarding Exclusivity For Generic Risperdal R

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of Columbia has granted a request of the Company's subsidiary, Teva Pharmaceuticals USA, Inc. that the U.S. Food and Drug Administration (FDA) relist in the Orange Book U.